Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 8/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | MTOR | P42345 | 4/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050577 | 0.88 | IKBKB (0.39) | ATRALOX5APFEN1GPR119PIK3CA | |
| SCHEMBL4373924 | 0.86 | GPR119 (0.38) | ATRGPR119 | |
| SCHEMBL4057221 | 0.86 | GPR119 (0.53) | ATRGPR119 | |
| SCHEMBL13690548 | 0.82 | JAK2 (0.44) | ATR | |
| SCHEMBL13690517 | 0.79 | MCHR1 (0.40) | ATRGPR119 | |
| SCHEMBL4058199 | 0.78 | GPR119 (0.51) | GPR119 | |
| SCHEMBL4055733 | 0.78 | IKBKB (0.41) | ATRGPR119PIK3CAMTORMAPK1 | |
| SCHEMBL4049265 | 0.76 | GPR119 (0.52) | GPR119MAPK1 | |
| SCHEMBL4370438 | 0.76 | ATR (0.44) | ATRPIK3CAMTOR | |
| SCHEMBL13690325 | 0.75 | FAAH (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009106561-A1 | PYRAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106561-A1 | PYRAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |